![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Olbetam |
AHFS/Drugs.com | UK Drug Information |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% |
Protein binding | None |
Metabolism | None |
Elimination half-life | Phase 1: 2 hrs Phase 2: 12–14 hrs |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.051.736 |
Chemical and physical data | |
Formula | C6H6N2O3 |
Molar mass | 154.125 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a lipid-lowering agent. It reduces triglyceride levels and increases HDL cholesterol. It may have less marked adverse effects than niacin, although it is unclear whether the recommended dose is as effective as standard doses of niacin.